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Abstract
Ignoring the indirect effects of vaccination has led to two types of inaccuracies in cholera vaccine policy analysis in endemic
settings. First, when herd protection is ignored, the social benefits and cost-effectiveness of vaccination programs are 
underestimated, such that the programs are rarely considered to be a wise use of scarce public health resources. Once vaccine 
herd protection is included, use of the vaccine can satisfy both social welfare objectives and benchmark cost effectiveness 
criteria. Second, design recommendations to implement programs considered most attractive without accounting for the effect of 
herd protection may not allow the capture of the greatest social benefits. The analysis summarized in this paper demonstrates that
it is possible to account for herd protection in both cost-effectiveness and cost-benefit calculations. In the former case, however,
it does pose significant interpretation challenges. When herd protection is incorporated into a cost-effectiveness model, cost-
effectiveness measures such as costs per DALY avoided become a function of vaccination coverage. When this is the case, there 
is no obvious decision objective in a cost-effectiveness analysis. Cost-benefit metrics, on the other hand, provide a clear 
economic argument for when to pursue vaccination efforts and how to design them. More sophisticated measurements of the 
economic benefits of vaccination should therefore become standard practice when evaluating the potential of vaccination 
programs.
© 2010 Published by Elsevier Ltd. 
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1. Introduction
Cholera is an infectious disease caused by exposure to the bacterium Vibrio cholerae O1 or O139, resulting in acute 
dehydration and sometimes death. In 2008 the World Health Organization (WHO) reported more than 190 000 cases 
worldwide and 5 143 deaths, although these estimates are widely regarded as low due to underreporting [1]. Severe 
cholera is treatable with intravenous rehydration therapy if the patient is diagnosed promptly and has access to basic 
health care facilities, but mortality risks in epidemic situations can reach 20 percent and higher [2]. Recent upward 
trends in WHO-reported cholera cases, the reemergence of cholera in parts of West Africa, and the continuing 
problem of endemic cholera in East Africa and several parts of Asia have prompted increasing concern over 
vulnerability to infection of poor populations living in unsanitary conditions.
Most public health experts believe that improved sanitation and hygiene is the best method for controlling cholera. 
However, such improvements have remained elusive in many locations, as evidenced by the persistence of cholera 
in many developing countries. Another approach is to combine prevention and preparedness activities. Surveys to 
determine the economic benefits have been shown to produce very plausible measures of the benefits of vaccination 
[10-13]. This strategy might involve more widespread use of new, safe, and more effective oral cholera vaccines 
(OCV), of which four have been licensed in some countries. One of these has been licensed in India following a trial 
in Kolkata and appears particularly promising because it is inexpensive, relatively easy to administer and can be 
taken out of cold storage for some time during vaccination campaigns, facilitating delivery [3]. Furthermore, there is 
evidence that cholera vaccination can result in significant herd protection: diminished risk of infection among non-
vaccinees and enhanced protection of vaccinees [4, 5]. In 2009, the WHO began recommending vaccination of 
children in places where incidence exceeds 1 in a thousand (6), and also stated that “the role of OCVs needs to be 
further assessed in view of their introduction into areas where they can make a difference” [1]. 
Arguments over the merit of such programs have typically focused on their low cost-effectiveness. The Disease 
Control Priorities (DCP) Project ranked cholera immunization for infants with WC/rBS (Dukoral) vaccine, which 
costs about $6-8 per dose, among the least cost-effective interventions targeting diarrheal disease, with cost 
effectiveness ratios of US$1 402 to US$8 357 per DALY (disability-adjusted life year) averted [7]. Murray et al. [8] 
found that vaccination was less cost effective (about $3 000/DALY averted) than several other control strategies, 
including cholera disease treatment ($10-160/DALY averted) and certain types of water and sanitation 
improvements ($430/DALY averted). However, recent analyses for the new, low-cost vaccine (which only costs 
about $1 per dose), show that cost-effectiveness can be much higher, especially when herd protection effects are 
included [9]. 
Herd protection however raises new difficulties for policy-makers who would base cholera vaccination program 
design on cost-effectiveness outcomes. In the presence of herd effects, measures such as average costs per DALY 
avoided become a function of vaccination coverage, such that there is no obvious decision objective in a cost-
effectiveness analysis. For example, choosing a coverage level that minimizes the costs per DALY avoided could 
result in a very low coverage level; expanding coverage might still save DALYs at low cost. Maximizing the 
number of DALYs avoided may result in very high marginal costs per DALY avoided if herd protection can reduce 
disease burden significantly at lower coverage rates.  
Cost-benefit metrics, on the other hand, provide a clear economic argument for when to pursue vaccination efforts 
and how to design them. These measures require careful nonmarket valuation studies of the demand for vaccines 
within a target population, which can be difficult because the vaccines are not usually available in private markets. 
Such studies are nonetheless possible and of vaccination should therefore become part of the standard toolkit for 
evaluating the potential of vaccination programs. 
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This paper summarizes the cost-effectiveness (Section 2) and cost-benefit models (Section 3) for vaccination 
programs, and discusses how herd protection can be included in each of them. These sections also briefly review the 
results obtained from using such models to evaluate potential cholera vaccination programs in Beira, Mozambique, 
where the disease is endemic. Section 4 concludes. 
2. Model of vaccine cost-effectiveness including herd protection 
Cost-effectiveness studies of vaccine programs typically report outcomes in terms of metrics such as the cost per 
case avoided or, in order to more fully account for the morbidity and mortality burden caused by the disease being 
targeted, the cost per DALY avoided [9, 14]. A crucial parameter in this calculation is the effectiveness of the 
vaccine over time Efft:
where YLD avoidedi,t and YLL avoidedi,t are the years of life in disability avoided and the years of life lost avoided in 
age group i and year t due to vaccination. Efft is the effectiveness of the vaccine in year t, Covi is the percentage of 
age group i that is vaccinated in the program, LEi, CFRi, Ii and Ni are the life expectancy, case fatality rate, cholera 
incidence and number of people in age group i, l is the average duration of the disease, Dur is the vaccine duration, 
wDALY is the DALY weight ascribed to cholera, and d is the discount rate. The parameter c is the cost of the vaccine 
per fully-immunized person, and COIpub, avoided is the public cost of illness avoided, which is equal to:  
where  is the public cost of illness per case of cholera in age group i.
If vaccination provides indirect protection to non-vaccinated members of the population, or provides additional 
protection to the vaccinated, equation 1 will underestimate the true cost-effectiveness [9]. In the presence of herd 
protection by vaccination the disease burden reduction will increase, which affects the COIpub, avoided and Efft terms in 
equation 1. Equations 1 and 2 must be modified to account for the fact that overall vaccine effectiveness is a 
function of the coverage in the N age groups in the population, or: 
It is certainly possible to use the correct measure of overall effectiveness from equation 3 rather than the one from 
equation 1. All that is needed is to carry out vaccine effectiveness studies capable of discerning the extent and nature 
of the herd effects from vaccinating different age groups, of which there are an increasing number [4, 15]. Then, 
overall effectiveness can be expressed as a function of coverage levels in those different age groups. Unfortunately, 
there is a larger problem with basing decisions on cost-effectiveness in this case: the cost per DALY avoided 
becomes a function of the level of vaccine coverage in the target population. This result is also obtained if there are 
economies or diseconomies of scale in a vaccination program, i.e. if the cost of vaccination is also a function of 
coverage, which seems plausible. On the one hand, choosing a coverage level that minimizes the cost per DALY 
avoided could result in a very low coverage level; expanding coverage might still save DALYs at very little cost 
[16]. On the other, simply maximizing the number of DALYs avoided will result in very high marginal costs per 
DALY avoided.  
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Results from calculations for cholera programs in Beira demonstrate that when we account for cholera herd 
protection, larger programs tend to have higher cost per DALY avoided than smaller programs (Table 1, data from 
ref [9]). For example, going from Program Option 1 targeting only school children, to Option 2 for all children, 
raises the cost per DALY avoided from $128 to $139. Further adding adults in a community-based program yields a 
cost per DALY avoided of $331. Results in other sites have shown similar trends [9]. This is because the marginal 
increases in vaccine effectiveness are decreasing with program size, and because incidence is lower in adults. Still, it 
is difficult to determine which level of cost-effectiveness is too high or too low. 
3.  Cost-benefit model of vaccination including herd protection 
In contrast to cost-effectiveness analysis, cost-benefit analysis offers a simple framework for choosing the level of 
vaccination coverage (via selection of the vaccine price p) that is most beneficial to society [17]. In this case, when 
there is no herd protection, a social planner’s objective is to maximize the net benefits of vaccination, where: 
where WTPiv is the average willingness-to-pay (total benefits) for a vaccinated individual in age group i for vaccines 
purchased at price p. WTPiv is increasing in p, because higher vaccine prices result in exclusion of individuals with 
willingness to pay less than the price that is charged. Individuals do not take account of the public cost of illness 
savings COIpub, avoided when choosing whether or not to obtain vaccines, so this must be added to the overall benefits 
of the program. The costs of vaccination are then debited from these two types of benefits to obtain the overall 
benefits of a program. 
When the vaccine provides significant herd protection, the planner’s objective must be modified to account for the 
benefits to unvaccinated persons. 
where WTPiu is the average willingness-to-pay (total benefits) for a unvaccinated individual in age group i for 
vaccines purchased at price p. WTPiv and WTPiu are each now a function of effectiveness  and , which are 
themselves dependent on coverage levels. Like WTPiv, WTPiu is increasing in p because the marginal individual 
excluded by increasing price p has higher demand for vaccines than the rest of the unvaccinated pool of individuals. 
Because WTPiv > WTPiu at all prices, though, the average private benefit (net of payments for vaccines) may be 
increasing or decreasing in p, depending on 1) the number of individuals who switch from the purchasing to non-
purchasing group, and 2) the extent of herd protection to the unvaccinated. COIpub, avoided now includes public cost-
of-illness savings to both the vaccinated and unvaccinated. 
One common objection to use of cost-benefit analysis for evaluation of vaccination programs is that the demand for 
vaccines – the terms WTPiv and WTPiu in equation 4 – are typically not known, because vaccines are not traded in 
markets. There are, however, a growing number of demand studies for cholera vaccines in developing countries, 
which have yielded plausible estimates of willingness-to-pay. These studies use both stated and revealed preference 
methodologies commonly used in the field of environmental economics [10-13]. The information from such studies 
has been used to conduct cost-benefit analysis of cholera vaccination programs in Beira, Mozambique and Kolkata, 
India [16, 17]. As with the cost-effectiveness results, these studies show that the net benefits of vaccination 
programs in Beira increase dramatically when herd protection is included in the calculations (Table 1, data from ref 
[16]).  
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Table 1. Outcomes of cost-effectiveness and cost-benefit analyses for cholera vaccination programs without 
user fees, in Beira, Mozambique (Results from (9) and (16)). 
Outcomes
Not including
herd protection 
Including herd 
protection
Option 1: School-based program targeting school 
children (5-14 yrs) 
Number of vaccinations 65,900 65,900 
Overall coverage (%) 12 12 
Cases avoided over 3 yrs 323 2,615 
Net public cost per DALY averted ($) 1,748 128 
Net benefits of program (thousands of US$) -16 454 
Option 2: School-based program targeting all 1-14 
yrs 
Number of vaccinations 89,300 89,300 
Overall coverage (%) 16 16 
Cases avoided over 3 yrs 672 3,393 
Net public cost per DALY averted ($) 1,081 139 
Net benefits of program (thousands of US$) 22 489 
Option 3: Community-based program (all persons 
1 yr and older) 
Number of vaccinations 257,600 257,600 
Overall coverage (%) 47 47 
Cases avoided over 3 yrs 1,772 5,692 
Net public cost per DALY averted ($) 1,353 331 
Net benefits of program (thousands of US$) -101 -28 
“Very cost effective” threshold (per capita GDP) $382 $382 
“Cost effective” threshold (3 x per capita GDP) $1,146 $1,146 
Note: Costs per fully-vaccinated individual (2 doses) were assumed to be the same for community and school-based programs.
The calculations also demonstrate some of the problems with cost-effectiveness metrics. First, programs that appear 
“very cost effective” may in fact be expensive from a social perspective, for example Option 3, which has a cost-
effectiveness ratio of $331/DALY averted (less than the $382 threshold for “very cost effective” programs) but 
results in negative net benefits. Second, programs which appear less cost-effective may in fact deliver higher net 
benefits (comparing Options 1 and 2, for example). In that case, expansion of the program to include all children 
results in higher cost per DALY averted ($139 versus $128), but that expansion is still worthwhile from a social 
perspective, since it provides an additional net benefit of about $35 000. 
4.  Conclusions 
This paper presented basic models for conducting cost-benefit and cost-effectiveness analyses that include herd 
protection. Such models have been applied in previously published research to analyze cholera vaccination program 
options in Beira, Mozambique, using site-specific data on disease incidence, willingness-to-pay for vaccines, and 
cost-of-illness [9, 16]. Here we compared the cost-effectiveness and cost-benefit outcomes obtained in those papers, 
for programs in Beira without user fees. The results showed that ignoring herd protection effects leads to major 
underestimates of both the net benefits and cost-effectiveness of cholera vaccination. Thus, at some point in the 
process of testing the field effectiveness of vaccines, studies should also be carried out that would allow detection of 
herd effects if they exist. 
While it is possible to include herd protection in cost-effectiveness models, doing so raises significant interpretation 
challenges. When herd protection is incorporated into a cost-effectiveness model, cost-effectiveness measures such 
as costs per DALY avoided become a function of vaccination coverage, and that there is no straightforward way to 
determine how many people should be targeted. Plus, the same result follows if vaccination program costs are 
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subject to economies or diseconomies of scale, which is likely to occur in most real world programs, depending on 
the characteristics of the sites and the preferences of individuals with regards to acquiring vaccines. 
Cost-benefit metrics, on the other hand, provide a clear economic argument for when it is socially-beneficial to 
pursue vaccination efforts, and how these can be designed to maximize net benefits. While this paper only presented 
results for programs without user fees, cost-benefit analysis can also be used to compare the outcomes of programs 
that charge different prices to vaccines [16]. Cost-benefit calculations do however require information that is not 
always collected in field research on the potential of vaccination programs, most notably on the demand (or 
willingness-to-pay) for vaccines. Even in Beira, where such information was obtained, there are questions about 
how much willingness-to-pay varies as a function of vaccine effectiveness, which is important to assess when 
conducting thorough cost-benefit analysis in the presence of herd effects [16]. More sophisticated measurements of 
the economic benefits of vaccination should therefore become standard practice when evaluating the potential of 
vaccination programs. 
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